Response: Concerns with conclusions in the article by Sherwood et al ‘Key differences between 13 KRAS mutation detection technologies and their relevance for clinical practice’

Detalles Bibliográficos
Autor principal: Sherwood, James
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5757469/
https://www.ncbi.nlm.nih.gov/pubmed/29346455
http://dx.doi.org/10.1136/esmoopen-2017-000294
_version_ 1783290863347040256
author Sherwood, James
author_facet Sherwood, James
author_sort Sherwood, James
collection PubMed
description
format Online
Article
Text
id pubmed-5757469
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-57574692018-01-17 Response: Concerns with conclusions in the article by Sherwood et al ‘Key differences between 13 KRAS mutation detection technologies and their relevance for clinical practice’ Sherwood, James ESMO Open Correspondence BMJ Publishing Group 2018-01-03 /pmc/articles/PMC5757469/ /pubmed/29346455 http://dx.doi.org/10.1136/esmoopen-2017-000294 Text en © European Society for Medical Oncology (unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/
spellingShingle Correspondence
Sherwood, James
Response: Concerns with conclusions in the article by Sherwood et al ‘Key differences between 13 KRAS mutation detection technologies and their relevance for clinical practice’
title Response: Concerns with conclusions in the article by Sherwood et al ‘Key differences between 13 KRAS mutation detection technologies and their relevance for clinical practice’
title_full Response: Concerns with conclusions in the article by Sherwood et al ‘Key differences between 13 KRAS mutation detection technologies and their relevance for clinical practice’
title_fullStr Response: Concerns with conclusions in the article by Sherwood et al ‘Key differences between 13 KRAS mutation detection technologies and their relevance for clinical practice’
title_full_unstemmed Response: Concerns with conclusions in the article by Sherwood et al ‘Key differences between 13 KRAS mutation detection technologies and their relevance for clinical practice’
title_short Response: Concerns with conclusions in the article by Sherwood et al ‘Key differences between 13 KRAS mutation detection technologies and their relevance for clinical practice’
title_sort response: concerns with conclusions in the article by sherwood et al ‘key differences between 13 kras mutation detection technologies and their relevance for clinical practice’
topic Correspondence
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5757469/
https://www.ncbi.nlm.nih.gov/pubmed/29346455
http://dx.doi.org/10.1136/esmoopen-2017-000294
work_keys_str_mv AT sherwoodjames responseconcernswithconclusionsinthearticlebysherwoodetalkeydifferencesbetween13krasmutationdetectiontechnologiesandtheirrelevanceforclinicalpractice

Ejemplares similares